First emergency approvals of vaccines and antibody drugs in less than a year are great achievements of modern biotechnology in our battle against the COVID-19 pandemic, but we still have no efficient therapeutics to cure severe COVID-19. Millions of lives remain at risk until we control the pandemic, and what if we will never reach herd immunity? Waiting for others to do the job cannot be the strategy, as well as betting only on vaccines.
The B.1.1.7 variant of SARS-CoV-2, which was first identified in the UK, may be associated with an increased risk of death, a Nature study suggests.
Roche to acquire GenMark Diagnostics, Inc., to access platform to test for broad range of pathogens with one patient sample.
While media reports suggest AstraZenecas COVID-19 jab might have caused blot clots, the EMA didn’t confirm a causal relationship.
Swiss Roche AG has missed the primary endpoint in the REMDACTA trial in patients with severe COVID-19 pneumonia.
Danish sustainable crop protection company, BioPhero AS, has raised $17m in Series A funding led by DCVC Bio.
German researchers have presented a new method to assess on-target and off-target effects of CRISPR-Cas nucleases or TALENs.
EMAs human medicines committee has started a rolling review of Sputnik V, a COVID-19 vaccine developed by Russias Gamaleya National Centre of Epidemiology and Microbiology.
Chemieanlagenbau Chemnitz (CAC) is realizing one of the first large-scale plants in Europe to use innovative co-processing to produce carbon-neutral fuels.
Kurma Parnters and Francee investment bank have launched a €50m project named Argobio that is aimed at identifiying the most genious biotech ideas and spin out companies.